Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 3: CagriSema cardiovascular outcomes study in established cardiovascular disease
jRCT2031220672Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, myocardial infarction (MI), stroke and 5 more comparing CagriSema once-weekly plus standard of care with Placebo once-weekly plus standard of care (2 arms). Primary endpoint: Time to first major adverse cardiovascular event (MACE). Started Mar 2023; status: active, not recruiting.
02
Drugs
CagriSema
03
Conditions
cardiac morbiditymyocardial infarction (MI)strokearteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031220672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220672.